Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease

Completed · Phase 3

Conditions studied: Crohn's Disease

In brief

The purpose of this study is to determine Efficacy, Pharmacokinetics, and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease

Key facts

Study ID

NCT00409682

Run by

Abbott

People needed

192

Starts

2007-04-01

Expected to finish

2010-05-01

Last updated by the study team

2011-08-04

Who can join

Age: 6 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects between the ages of 6 and 17, inclusive, prior to baseline dosing.
• Subjects with a diagnosis of Crohn's disease for greater than 12 weeks prior to screening, confirmed by endoscopy or radiologic evaluation.
• PCDAI > 30 despite concurrent treatment with an oral corticosteroid, and/or azathioprine (AZA) or 6-mercaptopurine (6-MP) or methotrexate (MTX) as defined below:
• Oral corticosteroid - Prednisone of ≥ 10 mg/day or equivalent, but not exceeding 40 mg, with a stable dose for at least two weeks prior to Baseline.
• Azathioprine or 6-MP - AZA dose of ≥ 1.5 mg/kg/day or 6-MP dose of ≥ 1 mg/kg/day rounded to the nearest available tablet formulation, or a dose that is the highest tolerated for the subject, in the opinion of the investigator (for example due to leukopenia, elevated liver enzymes, nausea, etc.) for at least 8 weeks prior to Baseline with a stable dose for at least 4 weeks prior to Baseline.
• MTX dose of ≥ 5 mg once weekly, either subcutaneously (SC), intramuscularly (IM), or orally for subjects whose body weight is ≥ 20 kg, or a dose that is the highest tolerated for the subject, in the opinion of the investigator (for example due to leukopenia, elevated liver enzymes, nausea, etc.) for at least 8 weeks prior to Baseline with a stable dose for at least 4 weeks prior to Baseline.
• MTX dose of 0.2 mg/kg, up to 5 mg, once weekly, either SC, IM, or orally for subjects whose body weight is < 20 kg, or a dose that is the highest tolerated for the subject, in the opinion of the investigator (for example due to leukopenia, elevated liver enzymes, nausea, etc.) for at least 8 weeks prior to Baseline with a stable dose for at least 4 weeks prior to Baseline.
• Concurrent therapy will not be required for subjects who within the past 2 years in the opinion of the Investigator have not responded to or could not tolerate systemic corticosteroids, AZA, 6-MP, or MTX as defined below:
• Corticosteroids:
• Failed to successfully respond to corticosteroids, or
• Medical complications and/or adverse events (AEs) from corticosteroids that in the judgment of their physician, precludes their use (e.g. psychosis, uncontrolled diabetes, osteoporosis, or osteonecrosis).
• Azathioprine, 6-MP or MTX: -
• Failed to successfully respond to these drugs or
• Medical complications and/or AEs that in the judgment of their physician, precludes their use (e.g. allergic reaction, pancreatitis, elevated liver enzymes, hepatitis or leukopenia).
• If female, subjects who were sexually active and were of child-bearing potential practicing an approved method of birth control throughout the study and for 150 days after study completion. Examples of approved methods of birth control included the following:
• Condoms, sponge,foam,jellies,diaphragm, or intrauterine device (IUD)
• Oral,parenteral, or intravaginal contraceptives for 12 weeks prior to adalimumab administration
• A vasectomized partner.
• Parent or legal guardian,as required,had voluntarily signed and dated an informed consent form (IFC), approved by an Institutional Review Board (IRB)/ Independent Ethics Committee (IEC).
• Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by Screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.
• Parent or legal guardian was willing to actively supervise storage and administration of study drug and to ensure that the time of each dose was accurately recorded in the subject's diary.
• Subjects who had previously received infliximab, providing the subject had an initial response and then discontinued use due to a loss of response, or discontinued use due to intolerance.

You may not qualify if…

• History of cancer or lymphoproliferative disease other than a successfully and completely treated cutaneous squamous cell or basal cell carcinoma or carcinoma-in-situ of the cervix.
• History of listeria, histoplasmosis, chronic or active hepatitis B infection, human immunodeficiency virus (HIV), an immunodeficiency syndrome, central nervous system (CNS) demyelinating disease, or active tuberculosis (TB) (receiving treatment or not receiving treatment), severe infections such as sepsis and opportunistic infections.
• Subject with infectious colitis, ulcerative colitis or indeterminate colitis as determined by the investigator and Abbott Medical Monitor.
• Subject with symptomatic known obstructive strictures.
• Subject who had surgical bowel resections within the past 24 weeks of the Baseline visit or planned any resection at any time point while enrolled in the study.
• Subject with an ostomy or ileo-anal pouch. (Subjects with a previous ileo-rectal anastomosis were not excluded).
• Subject who had short bowel syndrome as determined by the investigator.
• Subject who was currently receiving total parenteral nutrition (TPN).
• Females who were pregnant or were currently breast-feeding.
• Subject who had received any investigational chemical agent in the past 30 days or 5 half-lives prior to Baseline (whichever was longer).
• Subject who had received any investigational biological agent in the past 16 weeks or 5 half-lives prior to Baseline (whichever was longer).
• Subject who has had systemic antibiotic, antiviral or antifungal treatment(s) within 3 weeks prior to Baseline for any non-Crohn's related infections.
• Subject with a history of clinically significant drug or alcohol abuse in the last year.
• Subjects with a poorly controlled medical condition such as: uncontrolled diabetes, recurrent infections, unstable ischemic heart disease, moderate to severe heart failure, recent cerebrovascular accidents and any other condition which, in the opinion of the investigator or the Sponsor, would put the subject at risk by participation in the protocol.
• Subjects with positive C. difficile stool assay.
• Subject who previously used infliximab within eight weeks of Baseline.
• Subject who previously used infliximab and had not clinically responded at any time ("primary non-responder") unless subject experienced a treatment limiting reaction to infliximab.
• Previous treatment with any other anti-TNF agent except infliximab.
• Received previous treatment with adalimumab or previous participation in an adalimumab clinical study.
• Screening laboratory and other analyses showing any of the following abnormal results:
• Electrocardiogram (ECG) - with clinically significant abnormalities;
• Aspartate transaminase (AST) or alanine transaminase (ALT) >1.75 x the upper limit of the reference range;
• Total bilirubin ≥ 3 mg/dL;
• Serum creatinine > 1.6 mg/dL;
• Subjects on AZA, 6-MP, or MTX who had not been on these medications for at least 8 weeks prior to Baseline and on stable doses of these medications for at least 4 weeks prior to Baseline. Subjects who had been on AZA, 6-MP, or MTX who had discontinued these medications within 8 weeks of Baseline.

Where it is running

• Site Reference ID/Investigator# 10287 — Los Angeles, California, United States
• Site Reference ID/Investigator# 5223 — Orange, California, United States
• Site Reference ID/Investigator# 4984 — San Francisco, California, United States
• Site Reference ID/Investigator# 5222 — Aurora, Colorado, United States
• Site Reference ID/Investigator# 5676 — Hartford, Connecticut, United States
• Site Reference ID/Investigator# 4911 — Orlando, Florida, United States
• Site Reference ID/Investigator# 7640 — Orlando, Florida, United States
• Site Reference ID/Investigator# 5904 — Atlanta, Georgia, United States
• Site Reference ID/Investigator# 4316 — Chicago, Illinois, United States
• Site Reference ID/Investigator# 5901 — Maywood, Illinois, United States
• Site Reference ID/Investigator# 4912 — Indianapolis, Indiana, United States
• Site Reference ID/Investigator# 4317 — Baltimore, Maryland, United States
• Site Reference ID/Investigator# 5102 — Rochester, Minnesota, United States
• Site Reference ID/Investigator# 4285 — Saint Paul, Minnesota, United States
• Site Reference ID/Investigator# 3826 — Las Vegas, Nevada, United States
• Site Reference ID/Investigator# 6182 — Morristown, New Jersey, United States
• Site Reference ID/Investigator# 8801 — Buffalo, New York, United States
• Site Reference ID/Investigator# 3734 — Mineola, New York, United States
• Site Reference ID/Investigator# 4913 — New Hyde Park, New York, United States
• Site Reference ID/Investigator# 6257 — Chapel Hill, North Carolina, United States
• Site Reference ID/Investigator# 4909 — Cincinnati, Ohio, United States
• Site Reference ID/Investigator# 4914 — Columbus, Ohio, United States
• Site Reference ID/Investigator# 5892 — Philadelphia, Pennsylvania, United States
• Site Reference ID/Investigator# 6354 — Nashville, Tennessee, United States
• Site Reference ID/Investigator# 4983 — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.